



Iblias

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion/ Notification ¹ issued on	Commission Decision Issued ² / amended on	Product Information affected ³	Summary
IA/0010/G	This was an application for a group of variations. B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.e.3.b - Change in test procedure for the immediate packaging of the finished product - Other changes to a test procedure (including replacement or addition)	14/12/2017	n/a		

¹ Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

² A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

³ SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).



A31/0002	<p>Pursuant to Article 31 of Directive 2001/83/EC, Germany initiated a procedure on 6 July 2016 based on concerns resulting from the evaluation of data from pharmacovigilance activities.</p> <p>The PRAC was requested to assess the potential impact of the results of the SIPPET study (which concluded that recombinant factor VIII medicines had a higher incidence of inhibitor development than plasma-derived medicines), and to issue a recommendation as to whether the marketing authorisations of these products should be maintained, varied, suspended or revoked. The EMA concluded in September 2017 that there is no clear and consistent evidence of a difference in the incidence of inhibitor development between the two classes of factor VIII medicines: those derived from plasma and those made by recombinant DNA technology. Due to the different characteristics of individual products within the two classes, EMA concluded that the risk of inhibitor development should be evaluated individually for each medicine, regardless of class. The risk for each product will continue to be assessed as more evidence becomes available.</p>	14/09/2017	10/11/2017	SmPC and PL	Please refer to the assessment report: human coagulation factor VIII - EMEA/H/A-31/1448
WS/1253	<p>This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p>	02/11/2017	n/a		

	B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)				
IB/0008	B.II.e.z - Change in container closure system of the Finished Product - Other variation	06/06/2017	n/a		
PSUSA/2200/201608	Periodic Safety Update EU Single assessment - octocog alpha	05/05/2017	n/a		PRAC Recommendation - maintenance
N/0007	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	25/04/2017	10/11/2017	Labelling and PL	
T/0006	Transfer of Marketing Authorisation	27/03/2017	11/04/2017	SmPC, Labelling and PL	
WS/1119/G	This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.1.k - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - New storage site of MCB and/or WCB B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation	23/02/2017	n/a		
IAIN/0005/G	This was an application for a group of variations. A.5.a - Administrative change - Change in the name	03/02/2017	11/04/2017	Annex II and PL	

	and/or address of a manufacturer/importer responsible for batch release A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)				
N/0001	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	01/06/2016	11/04/2017	Labelling and PL	